Literature DB >> 20223900

Antimicrobial and immunomodulatory effect of clarithromycin on macrolide-resistant Mycoplasma pneumoniae.

Satoshi Kurata1, Haruhiko Taguchi2, Tsuguo Sasaki3, Yasunori Fujioka4, Shigeru Kamiya1.   

Abstract

Macrolide antibiotics are frequently administered to treat mycoplasmal pneumonia. However, macrolide-resistant Mycoplasma pneumoniae has recently been isolated from clinical specimens in Japan. Clarithromycin (CAM) is a 14-membered-ring macrolide that has host immunomodulatory activity. Here, we established a gnotobiotic mouse model that was monoassociated with macrolide-resistant M. pneumoniae, and pathologically and microbiologically analysed the effects of antibiotics against mycoplasmal pneumonia. We also examined the immunomodulatory activities of macrolide antibiotics in human lung carcinoma A549 cells in vitro and in a specific-pathogen-free (SPF) mouse model of pneumonia induced by M. pneumoniae antigen in vivo. CAM anti-mycoplasma antibiotics decreased the number of macrolide-sensitive and -resistant M. pneumoniae in the lungs of gnotobiotic mice. Thus, in SPF mice, CAM modulated pulmonary inflammation induced by M. pneumoniae antigens.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20223900     DOI: 10.1099/jmm.0.014191-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  6 in total

Review 1.  Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.

Authors:  P Zarogoulidis; N Papanas; I Kioumis; E Chatzaki; E Maltezos; K Zarogoulidis
Journal:  Eur J Clin Pharmacol       Date:  2011-11-22       Impact factor: 2.953

2.  Identification of a mechanism for lung inflammation caused by Mycoplasma pneumoniae using a novel mouse model.

Authors:  Takeshi Saraya; Koh Nakata; Kazuhide Nakagaki; Natsuki Motoi; Kuniko Iihara; Yasunori Fujioka; Teruaki Oka; Daisuke Kurai; Hiroo Wada; Haruyuki Ishii; Haruhiko Taguchi; Shigeru Kamiya; Hajime Goto
Journal:  Results Immunol       Date:  2011-11-11

3.  Macrolide-resistant Mycoplasma pneumoniae prevalence and clinical aspects in adult patients with community-acquired pneumonia in China: a prospective multicenter surveillance study.

Authors:  Yu-Dong Yin; Rui Wang; Chao Zhuo; Hui Wang; Ming-Gui Wang; Can-Mao Xie; Dan-Yang She; Xin Yuan; Ren-Tao Wang; Bin Cao; You-Ning Liu
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

4.  Role of IL-17A and IL-10 in the antigen induced inflammation model by Mycoplasma pneumoniae.

Authors:  Satoshi Kurata; Takako Osaki; Hideo Yonezawa; Ken Arae; Haruhiko Taguchi; Shigeru Kamiya
Journal:  BMC Microbiol       Date:  2014-06-13       Impact factor: 3.605

Review 5.  Novel aspects on the pathogenesis of Mycoplasma pneumoniae pneumonia and therapeutic implications.

Authors:  Takeshi Saraya; Daisuke Kurai; Kazuhide Nakagaki; Yoshiko Sasaki; Shoichi Niwa; Hiroyuki Tsukagoshi; Hiroki Nunokawa; Kosuke Ohkuma; Naoki Tsujimoto; Susumu Hirao; Hiroo Wada; Haruyuki Ishii; Koh Nakata; Hirokazu Kimura; Kunihisa Kozawa; Hajime Takizawa; Hajime Goto
Journal:  Front Microbiol       Date:  2014-08-11       Impact factor: 5.640

6.  Mycoplasma pneumoniae 23S rRNA A2063G mutation does not influence chest radiography features in children with pneumonia.

Authors:  Huan Deng; Jun Rui; Deyu Zhao; Feng Liu
Journal:  J Int Med Res       Date:  2017-07-31       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.